Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LTBP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LTBP1 Recombinant Protein (ECD-Fc / Specific Domain Fragments) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View LTBP1 Products |
| Gene Delivery | LTBP1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View LTBP1 Products |
| Benchmark Ab | Anti-LTBP1 Recombinant Antibody Recombinant positive control for binding and functional assays. |
View LTBP1 Products |
| Validator | LTBP1 siRNA Set For knockdown verification in functional cell-based assays. |
View LTBP1 Products |
| Related Target A | TGFB1 Primary functional partner; LTBP1 controls the latency and local activation of TGF-beta 1. |
View TGFB1 Products |
| Related Target B | ITGAV Integrin alpha-V interacts with the latent TGF-beta complex to trigger activation. |
View ITGAV Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Large molecular weight and complex disulfide-rich structure of full-length LTBP1 | Domain-specific recombinant fragments (e.g., C-terminal or TGF-beta binding domains) sequence-verified and expressed in HEK293 for native glycosylation. |
| Cross-reactivity within the LTBP family (LTBP2, LTBP3, LTBP4) leading to off-target effects | Homolog panel proteins strictly verified by mass spectrometry and high-purity chromatography (>95% purity) for counter-screening. |
| Lack of reliable positive controls for binding assays | Recombinant benchmark antibodies generated from clinical-stage/published sequences. |
| False positives in cellular phenotypic assays | Sequence-validated siRNA pools included for target-specific knockdown controls. |
Live LTBP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LTBP1 therapeutics is intensifying, with major players shifting focus from traditional systemic TGF-beta inhibition to localized activation blockades. Because systemic pan-TGF-beta inhibition is associated with severe toxicities (such as cardiotoxicity and bleeding disorders), targeting the latent complex via LTBP1 represents a highly selective alternative. As first-generation latent-TGF-beta therapies reach the clinic, the next wave of R&D is targeting the specific extracellular matrix-bound pools of latent TGF-beta controlled by LTBP1 to treat severe fibrotic diseases and overcome immunosuppression in cold tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Biotech / Academic Collaborations | Idiopathic Pulmonary Fibrosis (IPF), Solid Tumors | Blocking Assay (Need high-purity LTBP1 domain-specific proteins to block integrin-mediated activation) |
| Bispecific / Context-Independent Inhibitors | Biopharma Consortia | Myocardial Fibrosis, Immuno-oncology | Selectivity Screening (Need LTBP1 vs LTBP3/4 homolog panels to avoid systemic toxicity) |
| RNA Therapeutics / siRNA | Preclinical Startups | Hypertrophic Scarring, Localized Fibrosis | In vitro Knockdown Validation (Need sequence-validated siRNA controls and transfection-ready Lentivirus) |